Follow Madrigal Pharmaceuticals, Inc.. Every new filing, FDA action, and trial change, in your feed and a morning email, each linked to its source.
9 Stories, 8 about Madrigal Pharmaceuticals, Inc. 11 approved Program 54 recruiting Registered trials Nov 3 Latest story
Timeline 8 Pipeline 1 Trials 5
Pipeline by stage
Approved 1
Phase 3 primary completions, next 6 months
All trials by completion date Details
Headquarters West Conshohocken, PA Incorporated Delaware Industry Pharmaceutical Preparations Formerly MADRIGAL PHARMACEUTICALS, INC. (to 2026); SYNTA PHARMACEUTICALS CORP (to 2016) Also known as MDGL How the company describes itself Madrigal Pharmaceuticals develops Rezdiffra (resmetirom), an oral THR-β agonist for metabolic dysfunction-associated steatohepatitis with moderate to advanced fibrosis. The company is evaluating Rezdiffra in Phase 3 for compensated MASH cirrhosis. source